Abstract Library

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4182 DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide

Introduction: Temozolomide (TMZ), a standard therapy for pancreatic neuroendocrine tumors (pNETs), is an alkylating agent causing missense mutations and triggering cell death.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Reni A, Torresan I, Borghesani M, Rossi A,

Keywords: DNA Damage Repair, Tumor mutational burden, Neuroendocrine, Temozolomide,

#3979 New insights into the progression of NET G3 with a focus of NETs with NEC-like transformation

Introduction: Despite increasing knowledge of the clinical and morphomolecular features of NETs G3, little is known about NETs showing NEC-like transformation. Recent studies reported that NETs G3 may share histological and genetic features with NECs, such as TP53 mutations.

Conference:

Presenting Author:

Authors: Kasajima A, Moser E, Pfarr N, Ito A, Vogel L,

Keywords: Neuroendocrine Tumor, Progression, Transition, NEC-like NET,

#3530 Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: The Gustave Roussy experience

Introduction: Key molecular alterations (MA) of neuroendocrine neoplasm (NEN) of various grade/primaries have been described but the applicability of molecular profiling (MP) for precision medicine (PM) in NEN remains to be demonstrated.

Conference:

Presenting Author: Boilève A

Authors: Boilève A, Faron M, Bayle A, Mouren A, Lamartina L,

Keywords: Precision medicine, personalized treatment, neuroendocrine tumor, neuroendocrine carcinoma, molecular profile,

#3486 Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)

Introduction: HG GEP-NEN consist of well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinoma (NEC). The majority have advanced disease, limited treatment options and a poor prognosis.

Conference:

Presenting Author: Elvebakken H

Authors: Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe I,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade, gastroenteropancreatic, molecular alteration, molecular marker,